

Subscribe to
Bioshares
\$500/
48 issues

More details can be found
on the back page

Companies covered: **4DX, ARX, AT1, CUV, MDC, NYR, PXS, VHT**

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.6%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.4%
Year 7 (May '07 - May '08)	-35.8%
Year 8 (May '08 - May '09)	-7.4%
Year 9 (May '09 - May '10)	50.2%
Year 10 (May '10 - May '11)	45.4%
Year 11 (May '11 - May '12)	-18.0%
Year 12 (May '12 - May '13)	3.1%
Year 13 (May '13 - May '14)	26.6%
Year 14 (May '14 - May '15)	23.0%
Year 15 (May '15 - May '16)	33.0%
Year 16 (May '16 - May '17)	16.8%
Year 17 (May '17 - May '18)	-7.1%
Year 18 (May '18 - May '19)	-2.3%
Year 19 (May '19 - May '20)	39.5%
Year 20 (May '20 - Current)	23.2%
Cumulative Gain	1241%
Av. Annual gain (19 yrs)	17.3%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd.

Blake Industry & Market Analysis Pty Ltd
ACN 085 334 292
PO Box 193
Richmond Vic 3121
AFS Licence No. 258032
Enquiries for Bioshares
Ph: (03) 9326 5382
Fax: (03) 9329 3350
Email: info[at]bioshares.com.au

David Blake - Editor/Analyst
Ph: (03) 9326 5382
Email: david[at]bioshares.com.au

Mark Pachacz - Editor/Analyst
Ph: 0403 850 425
Email: mark[at]bioshares.com.au

Individual Subscriptions (48 issues/year)
\$500 (Inc.GST)
Edition Number 855 (10 August 2020)

Copyright 2020 Blake Industry and Market Analysis Pty Ltd. ALL RIGHTS RESERVED.
Secondary electronic transmission, photocopying, reproduction or quotation is strictly prohibited without written consent of the publisher.

Bioshares

10 August 2020
Edition 855

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies

Extract from Bioshares –

A Big Six Months Ahead for Pharmaxis

Pharmaxis (PXS: \$0.105) has four major milestones ahead in the next six months, which are likely to have a significant impact on the company's share price.

1. FDA Decision on Bronchitol

On 1 November the FDA will deliver a decision on the approval of Pharmaxis' cystic fibrosis drug, Bronchitol.

The drug is currently approved and sold into at least 17 countries around the world, predominantly in Europe and Australia, and should gain US clearance.

The most recent request by the FDA was for Pharmaxis' partner, Chiesi Farmaceutici, to alter its packaging and show that a lung function test for the drug (to ensure hypersensitive patients are not given the inhaled drug) can be easily conducted prior to prescription of the drug.

In FY2020, Bronchitol and Aridol (its lung function test) generated sales of \$7.0 million, up 24% over the previous year, with an adjusted EBITDA loss of \$4.0 million, down from \$5.0 million the previous year.

US approval will bring this business into profitability, with a US\$7 million milestone payment to be received following approval and a further US\$3 million payment upon launch.

The terms of these payments were recently adjusted to Pharmaxis' favour without penalty.

2. LOXL2 Licensing Deal

Pharmaxis CEO Gary Phillips said that the company still has active partnering discussions underway for its LOXL2 program. A deal was expected as early as last year with the company's share price under pressure until a deal is secured.

Pharmaxis recently completed an additional clinical study around the drug's blood profile based on different treatment regimens.

At this stage no further clinical work is anticipated until a licensing deal is secured.

3. Decision by Boehringer Ingelheim on Diabetic Retinopathy Program

In 2015 Boehringer Ingelheim acquired the compound now termed BI1467335, paying Pharmaxis \$83 million to date.

Boehringer has completed 9 clinical studies over the last four years with the compound in over 350 healthy volunteers, and in patients with NASH and diabetic retinopathy.

Cont'd over

One trial, which was looking at the effects of combining BI1467335 with tyramine on blood pressure was terminated, with the NASH program discontinued due to a drug interaction issue (presumably with tyramine, a chemical which can be found in certain cheeses).

Results from Boehringer's second study with BI1467335 in patients with diabetic retinopathy are due this half year. That study is looking at the highest dose of BI1467335 trialed in the NASH study. If there is a clear benefit, then subsequent (Phase II) studies in diabetic retinopathy may be considered at lower doses.

Pharmaxis' next potential milestone payment from this asset is from the commencement of Phase III studies. Results from the Phase IIa diabetic retinopathy trial are currently being assessed by Boehringer.

4. Commencement of Phase II Myelofibrosis Study

Pharmaxis has hired the CRO Parexel to conduct its Phase II study with its pan LOX inhibitor PXS-5505 in patients with myelofibrosis.

A 20,000 page IND submission was made to the FDA last month with clearance to commence the study to be received as early as this month. Pharmaxis has completed multiple trials in animal models and has completed Phase Ia and Phase Ib studies in volunteers showing a good safety profile and inhibition of the lysyl oxidase targets.

This is likely to be an open-label study which will allow data to be generated and reported during the trial. Effects of myelofibrosis included cytopenia and an enlarged spleen, the effects of which can be readily measured.

Once the myelofibrosis study is cleared, Phillips is expecting potential interest from independent investigators in other diseases, including pancreatic cancer (and in conjunction with PD-1 inhibitors) and in liver and oral cancer.

Potential Restructuring

Pharmaxis is in the process of evaluating a potential restructure of its business, which will involve how its mannitol (Bronchitol and Aridol) assets are best utilised and how best to fund its drug development business should Bronchitol receive FDA clearance in November.

This could include divesting of all or parts of the Bronchitol and Aridol business (in Bioshares view) as they move into profitability.

Summary

Pharmaxis is capitalised at \$42 million. The company held cash assets of just under \$20 million at the end of June, including an R&D tax rebate to be received this half.

Bioshares recommendation: **Speculative Buy Class A**

Bioshares

How Bioshares Rates Stocks

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating “Take Some Profits” means that investors may re-weight their holding by selling between 25%-75% of a stock.

Group A

Stocks with existing positive cash flows or close to producing positive cash flows.

- Buy** CMP is 20% < Fair Value
- Accumulate** CMP is 10% < Fair Value
- Hold** Value = CMP
- Lighten** CMP is 10% > Fair Value
- Sell** CMP is 20% > Fair Value
(CMP–Current Market Price)

Group B

Stocks without near term positive cash flows, history of losses, or at early stages commercialisation.

Speculative Buy – Class A

These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

Speculative Buy – Class B

These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

Speculative Buy – Class C

These stocks generally have one product in development and lack many external validation features.

Speculative Hold – Class A or B or C

Sell

Corporate Subscribers: Cogstate, LBT Innovations, Opthea, ResApp Health, Pharmaxis, Dimerix, Adalta, Actinogen Medical, Patrys, Cyclopharm, Antisense Therapeutics, Imugene, Exopharm, Immutep, Neuroscientific Biopharmaceuticals, Invex Therapeutics, Anteris Technologies

Disclaimer:

Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst DB: ACR,ADR,COH,CSL,CYC,MX1,OPT,SOM,TLX Analyst MP: ACR,CGS, CYC, OPT,CUV,MX1,PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than \$100 are not disclosed.

Subscription Rates (inc. GST)

48 issues per year (electronic distribution): **\$500**

For multiple email distributions within \$800 2-3 email addresses
 the same business cost centre, our \$1100 4-5 email addresses
 pricing structure is as follows: \$1370 6-10 email addresses

To subscribe, post/fax this subscription form to:

Bioshares
PO Box 193 Richmond VIC 3121
Fax: +61 3 9329 3350

I enclose a cheque for \$ _____ made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card \$ _____ MasterCard Visa

Card Number

Signature _____ Expiry date _____

Subscriber details

Name _____

Organisation _____

Ph () _____

Emails _____

The information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia and New Zealand, for subscribers to Bioshares, who are Australian or New Zealand citizens or commercial entities.